157 related articles for article (PubMed ID: 32516832)
1. MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period.
Kanni T; Argyropoulou M; Dinarello CA; Simard J; Giamarellos-Bourboulis EJ
Clin Exp Dermatol; 2021 Jan; 46(1):162-163. PubMed ID: 32516832
[No Abstract] [Full Text] [Related]
2. MABp1 Targeting IL-1α for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study.
Kanni T; Argyropoulou M; Spyridopoulos T; Pistiki A; Stecher M; Dinarello CA; Simard J; Giamarellos-Bourboulis EJ
J Invest Dermatol; 2018 Apr; 138(4):795-801. PubMed ID: 29129600
[TBL] [Abstract][Full Text] [Related]
3. Summaries for patients. Adalimumab for the treatment of hidradenitis suppurativa.
Ann Intern Med; 2012 Dec; 157(12):I-50. PubMed ID: 23247950
[No Abstract] [Full Text] [Related]
4. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial.
Kimball AB; Kerdel F; Adams D; Mrowietz U; Gelfand JM; Gniadecki R; Prens EP; Schlessinger J; Zouboulis CC; van der Zee HH; Rosenfeld M; Mulani P; Gu Y; Paulson S; Okun M; Jemec GB
Ann Intern Med; 2012 Dec; 157(12):846-55. PubMed ID: 23247938
[TBL] [Abstract][Full Text] [Related]
5. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials.
Lu JW; Huang YW; Chen TL
Medicine (Baltimore); 2021 Jun; 100(22):e26190. PubMed ID: 34087885
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure.
Arenbergerova M; Arenberger P; Marques E; Gkalpakiotis S
Int J Dermatol; 2020 Jun; 59(6):733-735. PubMed ID: 32012238
[No Abstract] [Full Text] [Related]
8. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
Harde V; Mrowietz U
J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
[TBL] [Abstract][Full Text] [Related]
9. Investigational drugs in clinical trials for Hidradenitis Suppurativa.
Theut Riis P; Thorlacius LR; Jemec GB
Expert Opin Investig Drugs; 2018 Jan; 27(1):43-53. PubMed ID: 29188733
[TBL] [Abstract][Full Text] [Related]
10. The cutting edge. Severe hidradenitis suppurativa treated with adalimumab.
Moul DK; Korman NJ
Arch Dermatol; 2006 Sep; 142(9):1110-2. PubMed ID: 16982997
[No Abstract] [Full Text] [Related]
11. Effective long-term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy.
Arenbergerova M; Gkalpakiotis S; Arenberger P
Int J Dermatol; 2010 Dec; 49(12):1445-9. PubMed ID: 21091684
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adalimumab in recalcitrant hidradenitis suppurativa.
Sotiriou E; Apalla Z; Vakirlis E; Ioannides D
Eur J Dermatol; 2009; 19(2):180-1. PubMed ID: 19153066
[No Abstract] [Full Text] [Related]
13. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
Ingram JR; Burton T
Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
[No Abstract] [Full Text] [Related]
14. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
15. A prospective open-label clinical trial of adalimumab for the treatment of hidradenitis suppurativa.
Amano M; Grant A; Kerdel FA
Int J Dermatol; 2010 Aug; 49(8):950-5. PubMed ID: 21128923
[TBL] [Abstract][Full Text] [Related]
16. Comparing treatment outcome of infliximab and adalimumab in patients with severe hidradenitis suppurativa.
van Rappard DC; Leenarts MF; Meijerink-van 't Oost L; Mekkes JR
J Dermatolog Treat; 2012 Aug; 23(4):284-9. PubMed ID: 21756155
[TBL] [Abstract][Full Text] [Related]
17. Hidradenitis suppurativa managed with adalimumab.
Yamauchi PS; Mau N
J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
19. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
[TBL] [Abstract][Full Text] [Related]
20. Biologic drugs for the treatment of hidradenitis suppurativa: an evidence-based review.
Shuja F; Chan CS; Rosen T
Dermatol Clin; 2010 Jul; 28(3):511-21, 523-4; quiz 522-3. PubMed ID: 20510761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]